Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 23OTHER 22NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Uterine Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 192Carboplatin 158pembrolizumab 116Bevacizumab 86liposomal doxorubicin 68Gemcitabine 62Cisplatin 54olaparib 49Topotecan 47Nivolumab 32niraparib 30Doxorubicin 29Cyclophosphamide 28Docetaxel 261-dodecylpyridoxal 22Injections 21Drug Therapy 20human papillomavirus vaccine, L1 type 16, 18 19atezolizumab 18Pemetrexed 18lenvatinib 17fludarabine 17mirvetuximab soravtansine 16Fulvestrant 16avelumab 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15durvalumab 14Oxaliplatin 13Irinotecan 13Fluorouracil 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Immunoglobulin G × Gynecologic × Clear all
NCT04424641 2023-07-25

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Genmab

Phase 1/2 Terminated
48 enrolled 20 charts
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Prostatic Neoplasms, Uterine Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡